{"schema_version":"secwatch.filing_event.v1","accession":"0000879169-23-000022","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.850384+00:00","generated_at":"2026-06-12T21:05:14.245640+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Incyte Q2 product revenue up 25% to $827M; raises Jakafi guidance; CSO departs","bullets":["Total net product revenue $827M (+25% YoY); Jakafi $682M (+14%), Opzelura $80M (+384%).","Raises Jakafi FY 2023 revenue guidance low end to $2.58-2.63B (from $2.55-2.63B).","Two pivotal trials met endpoints: ruxolitinib cream in pediatric AD (TRuE-AD3) and axatilimab in chronic GVHD (AGAVE-201).","CSO Dr. Dashyant Dhanak leaving effective Aug 2, 2023; oversaw 15+ IND filings during tenure."],"urls":{"canonical":"https://secwatch.observer/filing/0000879169-23-000022","json":"https://secwatch.observer/filing/0000879169-23-000022.json","markdown":"https://secwatch.observer/filing/0000879169-23-000022.md","text":"https://secwatch.observer/filing/0000879169-23-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000087916923000022/0000879169-23-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000087916923000022/incy-20230801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T21:05:14.245640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"305868f93d1d22f06494b104148308ef836d5223","claim":"INCYTE CORP reported second fiscal quarter ended June 30, 2023 results: revenue Total net product revenues of $827 million in the second quarter (Q2'23). Guidance raised.","evidence_excerpt":"Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs – Total net product revenues of $827 million in the second quarter (Q2'23) (+25% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $682 million (+14% Y/Y) in Q2'23; raising the bottom end of full year guidance to a new range of $2.58 - $2.63 billion for FY 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879169/000087916923000022/0000879169-23-000022-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second fiscal quarter ended June 30, 2023"},{"label":"Revenue","value":"Total net product revenues of $827 million in the second quarter (Q2'23)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}